Search Within

Yelena Yuriy Janjigian

Formats
  1. Meeting Abstract (217)
  2. Journal Article (156)
  3. Review (11)
  4. Editorial (6)
  5. Book Section (3)
  6. Guidelines (2)
  7. Research Letter (2)
  8. Conference Paper (1)
  9. Correspondence (1)
  10. Miscellaneous (1)
Groups
  1. Department of Medicine (400)
  2. Gastrointestinal Oncology Service (400)
  3. Solid Tumor Oncology Division (400)
  4. Center for Pancreatic Cancer Research (161)
  5. Surgery (148)
  6. Department of Pathology and Laboratory Medicine (137)

More Groups

People
  1. David Ilson (112)
  2. Geoffrey Ku (110)
  3. Laura Tang (84)
  4. David Kelsen (74)
  5. Steven Maron (65)
  6. Vivian Strong (65)

More People

Years
  1. 2025 (20)
  2. 2024 (33)
  3. 2023 (42)
  4. 2022 (37)
  5. 2021 (54)
  6. 2020 (23)

More Years

Publications
  1. Journal of Clinical Oncology (146)
  2. Annals of Oncology (44)
  3. Annals of Surgical Oncology (14)
  4. Annals of Surgery (13)
  5. Clinical Cancer Research (13)
  6. Oncology Research and Treatment (11)

More Publications

Publishers
  1. American Society of Clinical Oncology (152)
  2. Oxford University Press (51)
  3. American Association for Cancer Research (28)
  4. Springer (22)
  5. Elsevier Inc. (19)
  6. Elsevier Science, Inc. (17)

More Publishers

Results (400)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Induction FOLFOX and PET-directed chemoradiation for locally advanced esophageal adenocarcinoma
    Journal Article

    Carr, R. A.; Hsu, M.; Harrington, C. A.; Tan, K. S.; Bains, M. S.; Bott, M. J.; Ilson, D. H.; Isbell, J. M.; Janjigian, Y. Y.; Maron, S. B.; more...
    Annals of Surgery (2023)

    Fulltext@MSK | Save
  • First-line lenvatinib plus pembrolizumab plus chemotherapy versus chemotherapy in advanced/metastatic gastroesophageal adenocarcinoma (LEAP-015): Safety run-in results
    Meeting Abstract

    Yanez, P. E.; Ben-Aharon, I.; Rojas, C.; Acosta Eyzaguirre, D.; Hubert, A.; Araya, H.; Cohen, D. J.; Bai, L. Y.; Ghiringhelli, F.; Wyrwicz, L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • The role of education in adjusting to changes in clinical practice for gastric or gastroesophageal junction adenocarcinomas
    Meeting Abstract

    Ackbarali, T.; Janjigian, Y. Y.; Van Cutsem, E.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649
    Meeting Abstract

    Janjigian, Y. Y.; Shitara, K.; Moehler, M. H.; Garrido, M.; Gallardo, C.; Shen, L.; Yamaguchi, K.; Wyrwicz, L.; Skoczylas, T.; Campos Bragagnoli, A. S.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Differences in genomic profiles of gastric adenocarcinoma in the US and Japan
    Meeting Abstract

    Nakauchi, M.; Court, C.; Walsh, H. S.; Chatila, W. K.; Shimada, S.; Vardhana, S.; Tang, L. H.; Coit, D. G.; Janjigian, Y. Y.; Maron, S. B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Provider insights on managing patients on immunotherapy, barriers to clinical trials, and biomarker testing preferences
    Meeting Abstract

    Ackbarali, T.; Neal, J.; Janjigian, Y.; Overman, M.
    Journal for ImmunoTherapy of Cancer (2022)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 biomarker analyses
    Meeting Abstract

    Lei, M.; Janjigian, Y. Y.; Ajani, J. A.; Moehler, M.; Wang, X.; Shen, L.; Garrido, M.; Gallardo, C.; Yamaguchi, K.; Wyrwicz, L.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer - A randomized, double-blind, placebo-controlled, phase 3 study
    Meeting Abstract

    Janjigian, Y.; Van Cutsem, E.; Muro, K.; Wainberg, Z.; Al-Batran, S. E.; Hyung, W. J.; Molena, D.; Evans, B.; Ruscica, D.; Robbins, S. H.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Dose-escalation and dose-expansion study of trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2+gastric cancer (GC)/gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03
    Meeting Abstract

    Stein, A.; Lordick, F.; Janjigian, Y. Y.; Oh, D. Y.; Lee, K. W.; Steeghs, N.; Chao, Y.; DI Bartolomeo, M.; Garcia, M. D.; Mohammad, N. H.; more...
    Oncology Research and Treatment (2022)

    Fulltext@MSK | Save
  • Regorafenib (REGO) with nivolumab (NIVO) and FOLFOX in HER2 negative esophagogastric cancer (EGC)
    Meeting Abstract

    Cytryn, S.; Joshi, S.; Ku, G. Y.; Maron, S. B.; Desai, A.; Yang, J.; Rao, D.; Goldberg, Z.; Sugarman, R.; Antoine, A.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save